Brain, Vol. 122, No. 5, 807-816,
May 1999
© 1999 Oxford University Press
Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro
1 University Department of Neurology, Institute of Neurological Sciences, Southern General Hospital and 2 Department of Physiology and Pharmacology, Strathclyde University, Glasgow, Scotland, UK
Correspondence to:
Dr Hugh J. Willison, University Department of Neurology, Southern General Hospital, Glasgow, G51 4TF, UK E-mail: h.j.willison{at}udcf.gla.ac.uk
The neurophysiological effects of nine neuropathy-associated human anti-ganglioside antisera, three monoclonal antibodies to ganglioside GM1 (GM1) and of the cholera toxin B subunit (a GM1 ligand) were studied on mouse sciatic nerve in vitro. GM1 antisera and monoclonal antibodies from patients with chronic motor neuropathies and Guillain–Barré syndrome, and GQ1b/disialosyl antisera and monoclonal antibodies from patients with chronic ataxic neuropathies and Miller Fisher syndrome were studied. In vitro recording, for up to 6 h, of compound nerve action potentials, latencies, rise times and stimulus thresholds from isolated desheathed sciatic nerve was performed in the presence of anti-ganglioside antibodies and fresh human serum as an additional source of complement. No changes were observed over this time course, with 4–6 h values for all electrophysiological parameters being within 15% of the starting values for both normal and antibody containing sera and for the cholera toxin B subunit. Parallel experiments on identically prepared desheathed nerves performed with 0.5 nM saxitoxin led to complete conduction block within 10 min of application. Under identical conditions to those used for electrophysiological recordings, quantitative immunohistological evaluation revealed a significant increase in IgM (immunoglobulin M) deposition at nodes of Ranvier from 5.3 ± 3.1% to 28.7 ± 8.4% (mean ± SEM) of desheathed nerves exposed to three normal and three antibody containing sera, respectively (P < 0.03). Complement activation was seen at 100% of normal and 79% of disease-associated IgM positive nodes of Ranvier. These data indicate that anti-ganglioside antibodies can diffuse into a desheathed nerve, bind to nodes of Ranvier and fix complement in vitro without resulting in any overt physiological deterioration of the nerve over 4–6 h. This suggests that the node of Ranvier is relatively resistant to acute anti-ganglioside antibody mediated injury over this time scale and that anti-ganglioside antibodies and the cholera toxin B subunit are unlikely to have major direct pharmacological effects on nodal function, at least in comparison with the effect of saxitoxin. This in vitro sciatic nerve model appears of limited use for analysing electrophysiologically the effects of anti-ganglioside antibodies on nerve function, possibly because its short-term viability and isolation from circulating systemic factors do not permit the evolution of an inflammatory lesion of sufficient magnitude to induce overt electrophysiological abnormalities. In vivo models may be more suitable for identifying the effects of these antibodies on nerve conduction.
peripheral neuropathy; conduction block; autoantibodies; gangliosides; complement
CANOMAD = chronic ataxic neuropathy, ophthalmoplegia, monoclonal IgM protein, cold agglutinins and disialosyl antibodies
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Lonigro and J. J. Devaux Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis Brain, January 1, 2009; 132(1): 260 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Shavit, O. Beilin, A. D. Korczyn, C. Sylantiev, R. Aronovich, V. E. Drory, D. Gurwitz, I. Horresh, R. Bar-Shavit, E. Peles, et al. Thrombin receptor PAR-1 on myelin at the node of Ranvier: a new anatomy and physiology of conduction block Brain, April 1, 2008; 131(4): 1113 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Susuki, M. N. Rasband, K. Tohyama, K. Koibuchi, S. Okamoto, K. Funakoshi, K. Hirata, H. Baba, and N. Yuki Anti-GM1 Antibodies Cause Complement-Mediated Disruption of Sodium Channel Clusters in Peripheral Motor Nerve Fibers J. Neurosci., April 11, 2007; 27(15): 3956 - 3967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Zhang, P. H. H. Lopez, C. Y. Li, N. R. Mehta, J. W. Griffin, R. L. Schnaar, and K. A. Sheikh Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies Brain, May 1, 2004; 127(5): 1085 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Willison and N. Yuki Peripheral neuropathies and anti-glycolipid antibodies Brain, December 1, 2002; 125(12): 2591 - 2625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Gong, Y. Tagawa, M. P. T. Lunn, W. Laroy, M. Heffer-Lauc, C. Y. Li, J. W. Griffin, R. L. Schnaar, and K. A. Sheikh Localization of major gangliosides in the PNS: implications for immune neuropathies Brain, November 1, 2002; 125(11): 2491 - 2506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Prendergast and A. P. Moran Review: Lipopolysaccharides in the development of the Guillain-Barre syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies Innate Immunity, October 1, 2000; 6(5): 341 - 359. [Abstract] [PDF]
|
|
|
|
|
|
R. Kaji and J. Kimura Facts and fallacies on anti-GM1 antibodies: physiology of motor neuropathies Brain, May 1, 1999; 122(5): 797 - 798. [Full Text] [PDF]
|
|